Quantcast

Latest PregLem SA Stories

2008-08-19 03:00:13

Geneva, Switzerland, 19 August 2008 - PregLem SA, a Swiss biopharmaceutical company specialized in reproductive medicine, today announced the start of an international Phase III clinical trial program for PGL4001 (ulipristal) in symptomatic uterine myoma, a common benign solid tumor of the genital tract in women of reproductive age. PGL4001, an orally active, selective progesterone receptor modulator, was shown in a previous Phase II study to be well...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'